Author: Ravi Shankar

BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that members of its senior leadership team will present at the Jefferies Healthcare Conference in London taking place from November 16-19, 2026.

The presentation will feature a corporate overview and discussion of the Company’s recent positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS), following the Key Opinion Leader (KOL) call held on November 9, 2026.

Presentation Details
Event: Jefferies Healthcare Conference London
Date: Wednesday, November 18, 2026
Time: 14:30 GMT
Presenter: Ivor Elrifi, Chief Executive Officer

Management will also be available for one-on-one meetings throughout the conference. Interested parties may request meetings through the Jefferies conference portal or by contacting their Jefferies representative.

The recent Phase 2a INFORM-MS trial met its dual primary endpoints, including a statistically significant reduction in microglial activation as measured by TSPO PET imaging with the 50 μg dose of intranasal foralumab versus placebo (p=0.0168), along with a favorable safety and tolerability profile. Clinically meaningful and statistically significant improvements in fatigue were also observed in a secondary endpoint. These results were reviewed in detail during the Company’s KOL call with Tanuja Chitnis, M.D., principal investigator of the INFORM-MS trial, Tarun Singhal M.B.B.S, M.D., M.B.A., the Founding Director, NeuroPET Program Ann Romney Center for Neurologic Diseases, and Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board, Robert L. Kroc Professor of Neurology, Harvard Medical School and Co-Director, Ann Romney Center for Neurologic Diseases, BWH.

A replay of the KOL call is available at: https://edge.media-server.com/mmc/p/7ox8odig

Additional materials and information are available in the Investors section of the Company’s website: https://ir.tizianalifesciences.com/investors

About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. Intranasal foralumab is also currently being studied in additional Phase 2 trials in AD, ALS, and MSA.

Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana’s management and statements regarding completion of the INFORM-MS data analysis, presentation of detailed results, engagement with the FDA and potential further clinical development of intranasal foralumab. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

BALLERUP, Denmark, Nov. 12, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the third quarter of 2026.

Recent Financial Highlights

• Q3 2026 revenue was $4.4 million, an increase of 15.5% compared to $3.8 million in Q3 2025.
• Q3 2026 net loss was $(1.8) million, compared to $(1.5) million in Q3 2025.
• Q3 2026 Adjusted EBITDA was $(1.1) million, compared to $(0.5) million in Q3 2025.
• Cash and restricted cash totaled $13.9 million as of September 30, 2026, compared to $15.7 million as of June 30, 2026. The bridge loan obtained in May was fully repaid on July 22, 2026, which is reflected in the Company’s cash position as of September 30, 2026.

Outlook

• The Company maintains its full-year 2026 revenue guidance of $20 million to $23 million, representing approximately 21% to 39% growth year over year. Existing orders and backlog support a substantial portion of the low end of this range. Achievement of the guidance remains dependent on timely production, customer acceptance, shipment and revenue recognition. Revenue toward the upper end also depends on additional orders and project execution, including potential Water for Energy opportunities.
• Looking ahead to 2027, the Company believes its opportunity pipeline supports the potential for revenue growth of 30% to 40% compared with full-year 2026 revenue. This is a preliminary growth outlook based on current opportunities, not formal 2027 financial guidance, and remains subject to order conversion and project timing.

Management Commentary

“Our third-quarter results reflect continued commercial progress, with revenue increasing 15.5% year over year and sequential improvements in gross margin, net loss and Adjusted EBITDA,” said Fei Chen, Chief Executive Officer of LiqTech. “Across 2026, we have made important advances in our core markets. In Water for Industry, an initial system for a U.S. steel manufacturer has led to a follow-on order for four additional systems, and we secured a QureFlow system order for industrial cleaning-water reuse. In Commercial Aquatics, we expanded into Finland and advanced our first U.S. commercial installation. Our DPF business has regained momentum and entered the fourth quarter with a strong order backlog. In Marine, we secured projects across iCER, EGR and scrubber applications, with deliveries of all three system types planned during 2026.”

“We are maintaining our full-year revenue guidance of $20 million to $23 million. Revenue already recognized, together with our existing orders and backlog, provides meaningful visibility into fourth-quarter activity, particularly in industrial wastewater, Marine and DPF. Realizing that potential requires disciplined execution: completing production, meeting customer acceptance milestones and delivering systems on schedule so that revenue can be recognized before year-end. We remain focused on these priorities while maintaining cost discipline.”

“Throughout 2026, we have invested in developing a more robust opportunity pipeline to strengthen commercial execution and improve revenue visibility. Based on the opportunities currently identified, we believe the pipeline supports the potential for 30% to 40% revenue growth in 2027 relative to full-year 2026. This preliminary outlook is not formal guidance; converting opportunities into orders and revenue will depend on customer decisions and execution. Our priority remains building a scalable business and progressing toward sustainable profitability.”

Recent Operational Highlights

• Within Water for Industry, LiqTech continued execution of its $2.1 million follow-on order from a U.S.-based steel manufacturer for four additional QureFlow™ systems. The Company now expects these systems to be substantially completed by year-end with revenue recognized on a percent of completion basis. LiqTech is also progressing the QureFlow™ QF-6 system for Water Works Industrial Services, LLC at its new Freeport, Texas facility, with delivery expected in Q4 2026. The system is expected to recover more than 95% of incoming industrial equipment-cleaning wastewater for reuse as wash water, reducing freshwater consumption and disposal volumes. These projects demonstrate the application of LiqTech’s technology to demanding industrial wastewater streams and support its focus on repeatable deployments.
• Marine revenue was approximately $0.9 million in Q3 2026, compared to $0.5 million in Q3 2025. LiqTech delivered its third iCER water treatment system during the quarter. Two completed scrubber systems moved from the third-quarter delivery schedule to the fourth quarter due to the timing of customer Factory Acceptance Testing. The first of four previously ordered EGR water treatment systems remains scheduled for delivery in Q4 2026. In October, LiqTech also announced an order from Shanghai Qiyao Environmental Technology Co. Ltd. for two iCER water treatment units, expanding an existing scrubber customer relationship into an additional marine application.
• Commercial Pool revenue was approximately $0.8 million in Q3 2026, compared to $1.0 million in Q3 2025. Following quarter-end, LiqTech announced its first commercial Aquatics order in Finland, bringing its QlariFlow™ filtration technology to the Original Sokos Hotel Presidentti in Helsinki through local partner Pool4You. The project expands LiqTech’s geographic reach and is expected to provide a reference installation for future opportunities in Finland. Installation and initial operation of the Company’s first U.S. commercial pool system in Worland, Wyoming, are scheduled for November 2026.
• Diesel particulate filter (DPF) revenue was approximately $1.1 million in Q3 2026, compared with $0.8 million in Q3 2025. The raw-material availability issue that affected second-quarter production has been resolved, and the Company entered the fourth quarter with a strong DPF order backlog. Sales orders received from January 1 through November 1, 2026 increased 30% compared with the corresponding period in 2025.
• Plastics revenue was approximately $0.7 million in Q3 2026, compared to $1.0 million in Q3 2025. Following softer third-quarter activity, the Company has seen stronger orders entering the fourth quarter.

Q3 2026 Financial Results

Revenue for the three months ended September 30, 2026 was $4,396,894 compared to $3,807,274 for the same period in 2025, representing an increase of $589,620, or 15.5%. The increase reflected higher Systems and Aftermarket and Filters and Membranes revenue, including growth in Marine and Water for Industry, as well as contributions from externally funded research and development activities, partially offset by lower Components revenue.

Gross profit for the three months ended September 30, 2026 was $539,804, representing a gross profit margin of 12.3%, compared to $747,878, or 19.6%, for the same period in 2025, a decrease of $208,074, or 27.8%. The decline reflected a shift in revenue mix toward systems, particularly Marine, and away from aftermarket services, as well as lower manufacturing capacity utilization compared to the prior-year quarter, when production supported safety stock building. Depreciation included in cost of goods sold was $242,903 compared to $371,654 in the prior-year period. Sequentially, gross profit increased from $365,539 and gross margin improved from 8.4% in Q2 2026.

Total operating expenses for the three months ended September 30, 2026 were $2,334,674 compared to $2,080,880 for the same period in 2025, an increase of $253,794, or 12.2%. Foreign exchange rates were broadly comparable to the prior-year period. Operating expenses declined by $362,682, or 13.4%, compared to Q2 2026.

Selling expenses for the three months ended September 30, 2026 were $1,048,363 compared to $541,259 for the same period in 2025, an increase of $507,104, or 93.7%. The increase primarily reflected new hires within the commercial organization, costs associated with the U.S. Service Center and the reversal of bonus and other accruals in the prior-year period.

General and administrative expenses for the three months ended September 30, 2026 were $997,203 compared to $1,270,195 for the same period in 2025, a decrease of $272,992, or 21.5%. The decrease was supported by the timing of the annual general meeting, which moved to the fourth quarter in 2026. Included in general and administrative expenses was non-cash compensation of $218,252 and $258,538 for the third quarters of 2026 and 2025, respectively.

Research and development expenses for the three months ended September 30, 2026 were $289,108 compared to $269,426 for the same period in 2025, an increase of $19,682, or 7.3%. The increase primarily reflected membrane development costs and development of Marine and Commercial Pool systems.

Total other expense for the three months ended September 30, 2026 was $55,372 compared to $127,135 for the same period in 2025, a decrease of $71,763, or 56.4%. The decrease was primarily attributable to the repayment of debt in June 2026.

Net loss for the three months ended September 30, 2026 was $1,849,872 compared to $1,459,762 for the same period in 2025. Net loss attributable to LiqTech International, Inc. was $1,837,917, or $0.05 per basic and diluted share, compared to $1,431,913, or $0.10 per basic and diluted share, in the prior-year period.

Adjusted EBITDA for the three months ended September 30, 2026 was $(1,134,494) compared to $(505,891) for the same period in 2025.

Cash and restricted cash were $13,885,650 as of September 30, 2026, compared to $15,655,731 as of June 30, 2026 and $5,070,385 as of December 31, 2025.

Conference Call Details

Date and Time: Thursday, November 12, 2026, at 9:00 a.m. Eastern time

Webcast: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company’s website at https://www.liqtech.com/investor-relations/ or at https://app.webinar.net/GjlVNZKo5QA.

Replay: A webcast replay will be available at https://app.webinar.net/GjlVNZKo5QA.

About LiqTech International Inc.

LiqTech International, Inc., a Nevada corporation, is a high-tech filtration technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech’s silicon carbide membranes are designed to be used in the most challenging purification applications, and its silicon carbide filters are used to control diesel exhaust soot emissions. Using nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems, and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech’s SiC liquid membrane technology with the Company´s extensive systems design experience and capabilities, LiqTech offers unique, modular designed filtration solutions for the most difficult water purification applications.

For more information, please visit www.liqtech.com 

Follow LiqTech on Linkedln: http://www.linkedin.com/company/liqtech-international 

Follow LiqTech on Twitter: https://twitter.com/LiqTech

Forward–Looking Statement

This press release contains “forward-looking statements.”  Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements.  Readers are urged to carefully review and consider the various disclosures made by us in the reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation, and cash flows.  If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.  Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

We assume no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

LiqTech Company Contact
Susan Keegan Elleskov
Head of Marketing
LiqTech International, Inc.
Phone: +45 31315941
www.liqtech.com

LiqTech Investor Contact
Robert Blum
Lytham Partners, LLC
Phone: 602-889-9700
liqt@lythampartners.com

Use of Non-GAAP Financial Measures

In order to provide greater transparency regarding our operating performance, the financial results in this press release refer to a non-GAAP financial measure that involves adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management deems are not directly attributable to the Company’s core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance.

Adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) is defined by LiqTech as net loss or income adjusted for (i) income tax benefit or expense, (ii) total other expense or income, (iii) depreciation and amortization, (iv) amortization of right-of-use assets, and (v) stock-based compensation.

Management believes that the presentation of operating results using this non-GAAP financial measure provides useful supplemental information for investors by providing them with the non-GAAP financial measure used by management for financial and operational decision making, planning and forecasting and in managing the business. This non-GAAP financial measure does not replace the presentation of financial information in accordance with U.S. GAAP. These non-GAAP financial results should not be considered a measure of liquidity and is unlikely to be comparable to non-GAAP financial measures provided by other companies.

LIQTECH INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS
		September 30,				December 31,
		2026				2025
Assets
Current Assets:
Cash and restricted cash		$	13,885,650			$	5,070,385
Accounts receivable, net			4,645,103				3,429,992
Inventories, net			5,910,674				6,479,321
Contract assets			942,033				733,851
Prepaid expenses and other current assets			444,446				245,702
Total Current Assets			25,827,906				15,959,251
Non-Current Assets:
Property and equipment, net			5,010,594				5,845,323
Operating lease right-of-use assets			3,968,856				4,643,680
Deposits and other assets			553,488				545,573
Intangible assets, net			24,046				36,125
Goodwill			239,449				248,145
Total Non-Current Assets			9,796,433				11,318,846
Total Assets		$	35,624,339			$	27,278,097

LIQTECH INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
		September 30,				December 31,
		2026				2025
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable		$	1,759,885			$	1,552,890
Accrued expenses			2,308,093				1,795,382
Line of credit			89,489				–
Current portion of finance lease liabilities			491,529				517,759
Current portion of operating lease liabilities			728,539				714,446
Contract liabilities			602,184				140,986
Total Current Liabilities			5,979,719				4,721,463
Non-Current Liabilities:
Deferred tax liability			60,331				63,654
Finance lease liabilities, net of current portion			1,001,646				1,415,908
Operating lease liabilities, net of current portion			3,240,317				3,929,234
Loan from related party			1,193,183				1,265,057
Notes payable, net of debt discounts			–				5,510,545
Total Non-Current Liabilities			5,495,477				12,184,398
Total Liabilities			11,475,196				16,905,861
Stockholders’ Equity:
Preferred stock; par value $0.001, 2,500,000 shares authorized, 0 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively			–				–
Common stock; par value $0.001, 50,000,000 shares authorized and 32,947,841 and 9,627,064 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively			32,948				9,627
Additional paid-in capital			131,974,124				110,427,993
Accumulated deficit			(102,359,515	)			(94,795,121	)
Accumulated other comprehensive loss			(5,375,052	)			(5,209,173	)
Total Stockholders’ Equity			24,272,505				10,433,326
Noncontrolling Interest			(123,362	)			(61,090	)
Total Equity			24,149,143				10,372,236
Total Liabilities and Equity		$	35,624,339			$	27,278,097

LIQTECH INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
		For The Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Revenue		$	4,396,894			$	3,807,274			$	12,896,966			$	13,382,304
Cost of goods sold			3,857,090				3,059,396				11,597,879				12,024,792
				​				​				​				​
Gross Profit			539,804				747,878				1,299,087				1,357,512
				​				​				​				​
Operating Expenses:				​				​				​				​
Selling expenses			1,048,363				541,259				2,864,873				2,071,843
General and administrative expenses			997,203				1,270,195				4,001,123				4,171,764
Research and development expenses			289,108				269,426				836,987				742,105
				​				​				​				​
Total Operating Expenses			2,334,674				2,080,880				7,702,983				6,985,712
				​				​				​				​
Loss from Operations			(1,794,870	)			(1,333,002	)			(6,403,896	)			(5,628,200	)
				​				​				​				​
Other Income (Expense):				​				​				​				​
Interest and other income			80,398				64,354				119,633				197,710
Interest and other expense			(111,623	)			(63,391	)			(551,847	)			(175,140	)
Amortization of debt discount			–				(86,614	)			(489,455	)			(338,962	)
Gain (loss) on foreign currency transactions			(24,224	)			(39,932	)			(287,237	)			29,644
Gain (loss) on disposal of property and equipment			77				(1,552	)			(14,981	)			(65,016	)
				​				​				​				​
Total Other Expense			(55,372	)			(127,135	)			(1,223,887	)			(351,764	)
				​				​				​				​
Loss Before Income Taxes			(1,850,242	)			(1,460,137	)			(7,627,783	)			(5,979,964	)
				​				​				​				​
Income tax benefit			(370	)			(375	)			(1,117	)			(1,074	)
				​				​				​				​
Net Loss		$	(1,849,872	)		$	(1,459,762	)		$	(7,626,666	)		$	(5,978,890	)
				​				​				​				​
Net Loss attributable to noncontrolling interest			(11,955	)			(27,849	)			(62,272	)			(43,700	)
Net Loss attributable to LiqTech International, Inc.			(1,837,917	)			(1,431,913	)			(7,564,394	)			(5,935,190	)
				​				​				​				​
Loss Per Common Share – Basic and Diluted		$	(0.05	)		$	(0.10	)		$	(0.30	)		$	(0.40	)
				​				​				​				​
Weighted-Average Common Shares Outstanding – Basic and Diluted			38,247,720				14,916,470				24,845,406				14,916,470

		Three Months Ended September 30,								For the Nine Months Ended September 30,
			2026				2025				2026				2025
Net Loss (GAAP)		$	(1,849,872	)		$	(1,459,762	)		$	(7,626,666	)		$	(5,978,890	)
Income tax benefit		$	(370	)		$	(375	)			(1,117	)			(1,074	)
Total Other Expense		$	55,372			$	127,135				1,223,887				351,764
Depreciation & amortization		$	266,140			$	415,451				924,574				1,316,217
Amortization of right-of-use assets		$	175,986			$	153,123				523,674				434,762
EBITDA (Non-GAAP)			(1,352,744	)			(764,428	)			(4,955,648	)			(3,877,221	)
Stock-based compensation		$	218,250			$	258,537				654,900				730,335
Adjusted EBITDA (Non-GAAP)		$	(1,134,494	)		$	(505,891	)		$	(4,300,748	)		$	(3,146,886	)

Console unit sales increased 88% year-to-date versus prior-year period, expanding its installed base to drive future recurring circuit revenue

Advanced growth strategy with 510(k) submission for Aquadex label expansion and two product portfolio-expanding agreements leveraging existing sales force

Company to conduct conference call beginning at 9:00 a.m. Eastern time today

MINNEAPOLIS, Nov. 12, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and nine months ended September 30, 2026.

Third Quarter 2026 Financial Highlights

• Operating loss for the third quarter of 2026 improved 24% year over year to $2.1 million, driven by 430 basis points of gross margin expansion and a 13% reduction in operating expenses, primarily reflecting outsourced manufacturing efficiencies and efforts to align expenses with the highest-priority commercial and strategic programs.
• Net sales were $2.2 million in the third quarter of 2026, essentially unchanged versus the prior-year quarter, as the prior-year period benefited from fulfilling $0.4 million in accumulated backorders. Net sales increased 12% sequentially in the third quarter of 2026. For the nine months ended September 30, 2026, net sales increased 13% to $6.6 million compared with $5.8 million in the prior-year period, driven by growth in U.S. circuit and console sales.
• Pediatrics remained a significant growth driver, with net sales increasing 20% in the third quarter of 2026 and 26% year-to-date, compared with the prior-year periods.
• Sold 32 Aquadex consoles in the first nine months of 2026, an 88% increase compared with 17 consoles in the prior-year period. The expanded installed base provides a strong foundation for future recurring circuit revenue.
• Third-quarter 2026 gross margin expanded to 69.5% from 65.2% in the prior-year quarter, reflecting higher average selling prices and continued benefits from the Company’s contract manufacturing model. Year-to-date gross margin improved to 71.7%, compared with 59.4% in the prior-year period.
• Strengthened the Company’s balance sheet as of September 30, 2026, with $8.3 million in cash and cash equivalents.

Business Updates

• Submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of its Aquadex SmartFlow® System to include pediatric patients weighing five kilograms and above.
• A multicenter study titled “Kidney Support in Infants and Children using Aquadex: Findings From the ULTRA-Peds Registry” was accepted for publication in Pediatric Nephrology.
• Entered into a co-promotion and distribution agreement with Atrility Medical for its AtriAmp postoperative cardiac rhythm monitoring device, which leverages Nuwellis’ current pediatric and critical care sales force.
• Secured a second strategic distribution agreement with the exclusive U.S. distribution rights for the pediatric Zorro-Flow™ external urine collection system.

“We have made meaningful progress in strengthening Nuwellis both commercially and financially. Year to date, console unit sales have nearly doubled, expanding our installed base and creating a larger opportunity to grow recurring circuit revenue. Although our third quarter faced a tough comparison against the prior-year period when we fulfilled a significant backorder, the underlying momentum in our business remains strong, as evidenced by the growth in our pediatric segment,” said Mike McCormick, Nuwellis President and Chief Executive. “Further, by expanding gross margins and maintaining disciplined cost management, we significantly narrowed our operating loss and cash use during the quarter while continuing to invest in the areas that matter most to our long-term growth.

“We also delivered on several key strategic initiatives, including the submission of a 510(k) to the FDA to expand the Aquadex label to pediatric patients weighing as little as five kilograms, which, if cleared, could expand access and increase adoption. In addition, we secured distribution agreements with Atrility Medical and Zorro-Flow, which broaden our product offering in a capital-efficient manner through our established commercial infrastructure. We believe these achievements position Nuwellis for sustainable growth and long-term value creation for patients, customers and shareholders.”

Third Quarter 2026 Financial Results

Net sales for the third quarter of 2026 were $2.2 million, unchanged from the prior-year quarter, primarily due to a $0.4 million backorder in the third quarter of 2025. Net sales increased approximately 12% sequentially from the second quarter of 2026. In the third quarter of 2026, the pediatric segment demonstrated continued strength with an increase in net sales of 20% versus the prior-year period.

The Company sold eight Aquadex consoles during the third quarter, compared with 12 in the prior-year quarter. Through the first nine months of 2026, the Company sold 32 consoles, compared with 17 during the comparable 2025 period.

Gross margin for the third quarter of 2026 was 69.5%, compared with 65.2% in the prior-year quarter. The improvement reflected increased average selling prices and benefits from the Company’s transition to contract manufacturing.

Operating expenses decreased to $3.6 million from $4.1 million in the prior-year quarter, reflecting continued expense management and operational efficiencies.

In the third quarter of 2026, loss from operations improved 24% to $2.1 million, compared with $2.7 million in the prior-year quarter. Net loss was $2.0 million, compared with net income of approximately $0.5 million in the prior-year quarter, which included a significant noncash gain associated with changes in the fair value of warrant liabilities.

As of September 30, 2026, the Company had cash and cash equivalents of approximately $8.3 million. In July 2026, the Company raised $3.4 million in gross proceeds in a direct offering. Concurrently, the Company received gross proceeds of $3.3 million from the cash exercise of warrants. During the third quarter of 2026, the Company received $1.4 million in net proceeds from common shares sold under its ATM.

Webcast and Conference Call Information

The Company will host a conference call and webcast at 9:00 a.m. Eastern time today to discuss its third-quarter financial results and provide an update on the Company’s performance.

To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com/. Alternatively, the live conference call may be accessed by dialing (833) 309-3473 or (785) 838-9251 and using conference ID NUWEQ3. An audio archive of the webcast will be available following the call on the Investors page.

About Aquadex
The Aquadex SmartFlow System is indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

NUWELLIS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts)
		September 30,			December 31, 2025
		2026
ASSETS		(Unaudited)
Current assets
Cash and cash equivalents	$	8,290		$	1,085
Accounts receivable		1,391			1,493
Inventories, net		1,770			1,910
Other current assets		479			698
Total current assets		11,930			5,186
Property, plant and equipment, net		303			368
Operating lease right-of-use asset		120			293
Intangible assets, net		93			—
Other assets		999			271
TOTAL ASSETS	$	13,445		$	6,118
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued liabilities	$	1,986		$	2,226
Accrued compensation		700			460
Current portion of operating lease liability		135			261
Deferred consideration from Rendiatech acquisition, current		113			—
Other current liabilities		56			85
Total current liabilities		2,990			3,032
Deferred consideration from Rendiatech acquisition, non-current		200			—
Warrant liabilities		399			389
Operating lease liability		0			67
Total liabilities		3,589			3,488
Commitments and contingencies
Mezzanine Equity
Series J Convertible Preferred Stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 170 and 137, respectively		11			6
Stockholders’ equity
Series A junior participating preferred stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 30,000 shares, none outstanding		—			—
Series F convertible preferred stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 18,000 shares, issued and outstanding 27 and 127 shares, respectively		—			—
Series F-1 convertible preferred stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 100 shares, issued and outstanding 34 and 34 shares, respectively		—			—
Preferred stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 39,352,000 shares, none outstanding		—			—
Common stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 540,912 and 5,342, respectively		—			—
Additional paid-in capital		337,487			318,928
Accumulated other comprehensive income:
Foreign currency translation adjustment		8			8
Accumulated deficit		(327,650	)		(316,312	)
Total stockholders’ equity		9,845			2,624
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY	$	13,445		$	6,118

NUWELLIS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts and weighted average shares outstanding)
		Three months ended									Nine months ended
		September 30,									September 30,
			2026			2025					2026					2025
Net sales		$	2,212				$	2,217				$	6,584				$	5,846
Cost of goods sold			674					772					1,864					2,376
Gross profit			1,538					1,445					4,720					3,470
Operating expenses:
Selling, general and administrative			3,007					3,539					11,256					10,305
Research and development			584					603					3,254					1,828
Total operating expenses			3,591					4,142					14,510					12,133
Loss from operations			(2,053		)			(2,697		)			(9,790		)			(8,663	)
Other income			51					4					59					21
Financing expense			(61		)			–					(6,138		)			(10,553	)
Change in fair value of warrant liabilities			94					3,161					4,531					4,101
(Loss) income before income taxes			(1,969		)			468					(11,338		)			(15,094	)
Income tax expense			–					–					–					(5	)
Net (loss) income		$	(1,969		)		$	468				$	(11,338		)		$	(15,099	)
Deemed dividend attributable to Series J Convertible Preferred Stock			2					1					5					3
Net (loss) income attributable to common shareholders		$	(1,967		)		$	469				$	(11,333		)		$	(15,096	)
Basic and diluted (loss) income per share		$	(5.81		)		$	177.16				$	( 93.13		)		$	(12,548.83	)
Weighted average shares outstanding – basic and diluted			338,384					2,646					121,695					1,203
Other comprehensive loss:
Net (loss) income		$	(1,969		)			468					(11,338		)			(15,099	)
Foreign currency translation adjustments			–					(1		)			–					(7	)
Total comprehensive (loss) income		$	(1,969		)		$	467				$	(11,338		)		$	(15,106	)

NUWELLIS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)
	Nine Months ended
	September 30,
		2026				2025
Operating Activities:
Net loss	$	(11,338	)		$	(15,099	)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization		107				166
Stock-based compensation expense		55				103
Change in fair value of warrant liabilities		(4,531	)			(4,101	)
Financing expense		6,138				10,553
Non-cash IP R&D from Rendiatech acquisition		757				–
Changes in operating assets and liabilities:
Accounts receivable		102				586
Inventory, net		190				(471	)
Other current assets		219				(461	)
Other assets		(554	)			108
Other liabilities		(221	)			(74	)
Accounts payable and accrued expenses		(196	)			910
Net cash used in operating activities		(9,272	)			(7,780	)
Investing Activities:
Purchases of property and equipment		(17	)			(102	)
Purchase of intangible assets		(90	)			–
Cash paid for acquisition of Rendiatech, net of cash acquired		(164	)			–
Net cash used in investing activities		(271	)			(102	)
Financing Activities:
Proceeds from issuance of common stock and warrants, net		15,392				3,999
Issuance of common stock from ATM, net		1,358				1,889
Net cash provided by financing activities		16,750				5,888
Effect of exchange rate changes on cash		—				(7	)
Net increase (decrease) in cash and cash equivalents		7,207				(2,001	)
Cash and cash equivalents, and restricted cash – beginning of period		1,190				5,095
Cash and cash equivalents, and restricted cash – end of period	$	8,397			$	3,094
Cash and cash equivalents – end of period		8,290				3,094
Restricted cash – end of period		107				—
Cash and cash equivalents, and restricted cash – end of period	$	8,397			$	3,094

Supplemental cash flow information
Series C warrant conversion to equity	$		5,031			$				–
Series D warrant exercises	$		1,438			$				–
Deferred costs issued as consideration in asset acquisition	$		313			$				–
Common stock issued as consideration in asset acquisition	$		162			$				–
Series A warrants conversion to equity	$		–			$				8,439
Series B warrant exercises	$		–			$				2,055
Issuance of common stock for conversion of Series F-1 Preferred Stock	$		–			$				1,100
Deemed dividend on Series J Preferred Stock	$		5			$				3

• U.S. Patent No. 12,780,831 covers posiphen (buntanetap) D-tartrate Form B, a highly crystalline dihydrate, together with pharmaceutical compositions and methods of preparation, providing protection through 2044
• Form B is used in the Company’s ongoing pivotal Phase 3 trial in early Alzheimer’s disease and in the open-label extension Parkinson’s study
• Issued patent strengthens the Company’s intellectual property position ahead of the top-line data readout from its fully enrolled pivotal Phase 3 Alzheimer’s trial

MALVERN, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,780,831, titled “Solid Forms of Posiphen D-Tartrate.”

The patent contains eleven claims directed at the new crystalline form of buntanetap, designated Form B. The claims cover the Form B solid form, as characterized by its X-ray powder diffraction pattern and crystal unit cell, and at high purity levels – greater than 99.5% as determined by high-performance liquid chromatography (HPLC). The claims also cover methods of preparing Form B from earlier anhydrous Form A as well as pharmaceutical compositions containing Form B and a pharmaceutically acceptable carrier.

“Securing composition of matter protection for the new crystal form of buntanetap is an important milestone for Annovis,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. “This patent covers the form of buntanetap (Form B) that we have moved into our clinical program, and it strengthens our position as we approach the readout of our pivotal Phase 3 Alzheimer’s study and prepare for regulatory submissions that will follow.”

The patent provides Annovis with protection of buntanetap Form B through June 21, 2044.

About the New Crystalline Form
As described in the patent, Form B is a highly crystalline dihydrate, while the previously used Form A is a semi-crystalline anhydrate. The two forms do not readily interconvert and have distinct crystalline phases. Form B was characterized as a robust and stable dihydrate: it does not lose water or change form when dried under vacuum, and it shows no change in form or crystallinity after milling. An HPLC analysis reported 99.9% purity of Form B.

The pharmacokinetic comparison of Form B with Form A across mice, dogs and humans revealed comparable profiles for both forms in plasma, brain, and cerebrospinal fluid. The results were submitted to the FDA and have been published in a peer-reviewed manuscript in Biomolecules journal.

Background

• In June 2024, Annovis announced the filing of a composition of matter patent application for new solid forms of buntanetap.
• In July 2024, the Company announced that the U.S. Food and Drug Administration (FDA) cleared the transition to the new crystalline form in future clinical trials, after reviewing bridge studies comparing Form A with Form B, together with data on the Company’s new large-scale manufacturing process for that form.
• On November 3, 2026, Annovis was granted U.S. Patent No. 12,780,831 which covers the new crystalline form of buntanetap (Form B) that is used in the Company’s ongoing clinical trials.

Clinical Development Update
Annovis has completed enrollment in its pivotal Phase 3 trial (NCT06709014) evaluating once-daily oral buntanetap (Form B, 30 mg) in patients with early AD who are positive for the plasma biomarker pTau217. The trial is designed with two pre-specified readouts: a 6-month analysis of symptomatic effects and an 18-month analysis of disease-modifying effects. The Company expects the symptomatic top-line data readout in Q1 2027 and the disease-modifying readout in Q1 2028. Annovis has begun preparation for New Drug Application (NDA) submissions that will follow each readout.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

BOCA RATON, FL, Nov. 12, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced its unaudited financial results for the third quarter ended September 30, 2026, and released its quarterly shareholder letter.

Shareholder Letter Highlights

• SOL per share (“SPS”) increased more than 20% from August 12 through September 30. 2026.
• Net asset value (“NAV”) per share more than quadrupled over the same period, increasing over 300% from August 12 through September 30, 2026.
• Total SOL and SOL equivalents increased to 2,549,137 at September 30, up approximately 10% from the August 12 earnings update.
• SOL-denominated borrowings declined approximately 13%, from 562,000 SOL on August 12 to 487,000 SOL on September 30.
• Cash, cash equivalents, stablecoins, and marketable securities more than doubled from June 30 to September 30, strengthening the Company’s flexibility to fund operations and pursue treasury growth.
• Launched CHAD (Nasdaq: CHAD), establishing a perpetual source of capital intended to grow SOL holdings without issuing common shares, with no stated maturity or scheduled principal repayment.

Recent Developments

• CHAD first closed at its $10 stated amount (“par”) just 48 calendar days after its trading debut, faster than either Strive’s SATA or Strategy’s STRC, measured from trading debut to the first closing price at or above par.
• CHAD’s annual dividend rate increased to 14%, effective November 2, with daily cash dividends when declared. The Company is focused on broadening CHAD’s investor base, deepening liquidity, and scaling issuance on attractive terms.
• Total SOL and SOL equivalents reached 2,609,829 as of November 9, up approximately 13% from August 12, following nine consecutive weeks of SOL purchases.

Read the Shareholder Letter
The full Q3 2026 Shareholder Letter, including financial results, treasury strategy, CHAD credit metrics, and calculation methodologies, is available at: https://defidevcorp.com/earnings.

Management’s business update video will be available at approximately 11:00 a.m. Eastern Time on November 12, 2026, at youtube.com/@DeFiDevCorp, addressing strategic highlights and questions submitted by shareholders and sell-side analysts.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements regarding business strategies and prospects, capital deployment plans, expected cost savings, and expectations regarding future financial and operating metric reporting and targets, including SPS and future SOL price, and can be identified by words such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated losses that the Company may incur as a result of a decrease in the market price of SOL; (ii) a failure for the demand for SOL, or activity on the SOL network, to continue to develop and grow as predicted in our DFDV Model or at all; (iii) volatility in our stock price, including due to future issuances of common stock and securities convertible into common stock; (iv) the effect of and uncertainties related to the ongoing volatility in interest rates; (v) our ability to achieve and maintain profitability in the future; (vi) the impact on our business of the regulatory environment and complexities of complying with such environment including changes in securities laws or other laws or regulations; (vii) changes in the accounting treatment relating to the Company’s SOL holdings; (viii) our ability to respond to general economic conditions; (ix) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (x) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth and (xi) other risks and uncertainties more fully described in the section captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and other reports we file with the Securities and Exchange Commission.

As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

SPS and NAV per share are supplemental, management-defined analytical measures used to assess the Company’s treasury strategy and net SOL exposure attributable to common shareholders. The growth comparisons cover August 12 through September 30, 2026. SPS growth uses a constant SOL price of $117.99 and values both convertible notes at outstanding principal. NAV per share growth uses SOL prices of $75.53 and $117.99 on the respective dates and values the July 2030 convertible notes at 64.0% and 66.5% of outstanding principal, respectively; the April 2030 notes remain valued at principal. NAV includes the value of SOL and SOL equivalents, cash, stablecoins, and marketable securities, less SOL-denominated borrowings, convertible debt valued under the applicable methodology, other debt, and preferred equity at its aggregate stated amount. Both comparisons use adjusted common shares outstanding, including shares underlying restricted stock units and vested options, without assuming conversion of convertible debt or including incremental warrant shares. These measures do not represent GAAP book value, liquidation proceeds, or shareholder investment returns. Additional methodology and limitations appear in the shareholder letter.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

(All amounts in Canadian dollars unless otherwise noted)

TORONTO, Ontario, Nov. 12, 2026 (GLOBE NEWSWIRE) — Cadillac Mines Corporation (TSX: CADY) (“Cadillac Mines” or the “Company”) today announces that the Company has filed its unaudited condensed consolidated interim financial statements and related notes thereto, as well as its Management’s Discussion and Analysis (MD&A), for the three and nine months ended September 30, 2026, and 2025. The 2026 third quarter financial statements and MD&A are available on the Company’s website at www.cadillacmines.com and have been filed on the Company’s profile on SEDAR+ at www.sedarplus.ca.

Cadillac Mines finished the third quarter with cash and equivalents of $280.0 million and no debt.

Rick Howes, Chief Executive Officer of Cadillac Mines, stated, “Though the last few months have been challenging across the broader gold market, as we look at our business specifically we are very pleased the exploration success we have had across the portfolio and the continued advancement of our ongoing technical and environmental studies. Most importantly, our strong treasury positions us with sufficient working capital to execute on our plans through 2027 and beyond.”

At the end of the third quarter, Cadillac Mines had cash and equivalents of $280.0 million leaving the Company well positioned to advance its multiple value-enhancing initiatives including: exploration, permitting, environmental and engineering studies.

About Cadillac Mines

Cadillac Mines Corporation is a Canadian mineral exploration company advancing a growing portfolio of gold and critical mineral projects along the prolific Cadillac-Larder Lake Break in Ontario and Québec. Anchored by the historic Kerr-Addison Mine, the Company is focused on expanding its gold resource base, advancing the Geminid nickel deposit and unlocking the broader potential of its district-scale Abitibi land position. Through disciplined exploration, technical excellence and responsible development, Cadillac Mines is working to create lasting value for shareholders, communities and other stakeholders. For more information about the Company, please visit www.cadillacmines.com.

Forward-Looking Statements

This news release may contain forward-looking information within the meaning of applicable securities laws. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Forward-looking information includes, but is not limited to, statements with respect to anticipated future working capital requirements and anticipated development work. Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by the Company to be appropriate and reasonable as of the date of this release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, factors discussed under “Risk Factors” in the Supplemented Prospectus. Cadillac Mines undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws.

For further information, please contact:

Hannes Portmann, Chief Financial Officer
hportmann@cadillacmines.com

PRINCETON, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable formulation of nimodipine that has completed a Phase 3 clinical trial and is being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended September 30, 2026.

“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “Our dual-source manufacturing strategy to address potential remediation issues at our current contract manufacturer is progressing, and the timing of our NDA resubmission will reflect whichever manufacturing site reaches readiness first. The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission. We look forward to reporting our progress as we work toward achieving these important milestones.”

Second Quarter 2027 and Recent Corporate Highlights

• Completed a $10 million private placement financing with certain institutional and accredited investors. The Company intends to use the net proceeds from the financing to support the manufacturing and regulatory work needed to advance GTx-104.
• Announced receipt of the FDA meeting minutes from a Type A Meeting held with the FDA to discuss the CRL issued on April 23, 2026. The FDA did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data. The Company is working on its previously disclosed plan to address the identified issues and will report progress as key milestones are achieved.
• Initiated a dual-source manufacturing strategy for GTx-104 to address potential remediation issues from its current contract manufacturing organization (CMO). The Company’s current CMO has responded to the FDA, submitted a corrective action plan, and, the Company believes, is executing that plan in direct communication with the FDA. Reinspection timing depends on the current CMO’s readiness and FDA scheduling. In parallel, technology transfer was initiated during the quarter ended September 30, 2026 to a second, U.S.-based CMO, starting with analytical method transfer. The Company has also initiated the required non-clinical studies. The NDA resubmission may be supported by either CMO, or both, and its timing will reflect the pathway that reaches readiness first.

Second Quarter 2027 Financial Results

The Company reported a net loss of $2.1 million, or $0.11 per share, for the three months ended September 30, 2026, an increase of $1.2 million from the net loss of $0.9 million, or $0.06 per share, for the three months ended September 30, 2025. The increase in net loss was primarily due to a $1.4 million favorable change in the fair value of derivative warrant liabilities recorded during the three months ended September 30, 2025 with no such activity recorded in the three months ended September 30, 2026 as the applicable warrants have expired, as well as an increase in research and development expenses of $0.3 million, offset partially by a $0.6 million decrease in general and administrative expenses.

Total research and development expenses for the three months ended September 30, 2026 were $0.9 million, compared to $0.6 million for the three months ended September 30, 2025. The increase of $0.3 million primarily reflected higher third-party research activities related to the dual-source manufacturing strategy for GTx-104 and the required non-clinical studies identified in the CRL.

General and administrative expenses were $1.4 million for the three months ended September 30, 2026, a decrease of $0.6 million from $2.0 million for the three months ended September 30, 2025. The decrease was primarily the result of a $0.3 million decrease in professional fees primarily related to decreased legal fees, a $0.1 million decrease in pre-commercial planning activities for GTx-104, and a $0.1 million decrease in salaries and benefits.

Cash Runway

As of September 30, 2026, cash and cash equivalents were $21.3 million, a net increase of $4.3 million compared to cash and cash equivalents of $17.0 million at March 31, 2026. Cash used in operations for the six months ended September 30, 2026 was approximately $5.0 million. As announced in August 2026, the Company completed a private placement of its common stock with certain institutional and accredited investors. Net proceeds to the Company were $9.2 million. The Company plans to use its existing cash and cash equivalents towards resolving the items cited in the FDA’s CRL, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents will be sufficient to sustain planned operations, including the activities to address the items cited in the CRL, through the end of calendar 2028.

About aneurysmal Subarachnoid Hemorrhage (aSAH)

aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is aSAH, a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients per year.

About GTx-104

GTx-104 is a novel, injectable formulation of nimodipine that has completed a Phase 3 clinical trial and is being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to nimodipine oral capsules.

About Grace Therapeutics

Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.

For more information, please visit: www.gracetx.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Grace Therapeutics to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “estimates,” “potential,” “should,” “may,” “will,” “plans,” “continue,” “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including, but not limited to, statements regarding the Company’s cash runway and its planned uses of its existing cash and cash equivalents; the Company’s intended uses of the net proceeds from the August 2026 financing; future prospects of GTx-104; the Company’s belief that the issues identified by the FDA in the CRL can be successfully addressed in the Company’s resubmission of the NDA for GTx-104; the Company’s planned approach to addressing the items cited in the CRL; the Company’s dual source manufacturing strategy, including remediation at its current contract manufacturer and technology transfer to a second, U.S.-based contract manufacturer; the timing and outcome of any FDA reinspection of the current contract manufacturer; the Company’s belief that its current contract manufacturer is executing the corrective action plan in direct communication with the FDA; the Company’s plans to complete the required non-clinical studies; the Company’s plans to report progress against key milestones; GTx-104’s potential to bring enhanced treatment options to patients suffering from aSAH; the ability of GTx-104 to potentially eliminate the need for nasogastric tube administration in unconscious or dysphagic patients; the potential of GTx-104 to lower food effects, drug-to-drug interactions, and to eliminate potential dosing errors; the potential of GTx-104 to better manage hypotension in aSAH patients; and the Company’s intellectual property estate for GTx-104, are based upon Grace Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the timing and success of any regulatory resubmission of the NDA for GTx-104; (ii) the ability of the Company’s current contract manufacturer to regain compliance and generate the required leachables data, the timing of any FDA reinspection of that contract manufacturer, and that facility’s compliance status, which are determined by the FDA and outside the Company’s control, and the FDA’s position that it will not approve the NDA while the facility remains in an unacceptable compliance status; (iii) the ability of a second, U.S.-based contract manufacturer to complete the technology transfer, manufacture three registration batches, generate the required 12 months of stability data, analytical data and leachables data, and complete a product-specific pre-approval inspection; (iv) the need to complete additional non-clinical studies; (v) the requirement that any resubmission comprehensively address all items cited in the CRL and the risk of review delay; (vi) the Company’s potential need for additional capital, which may not be available on acceptable terms; (vii) changes to regulatory pathways; (viii) the Company’s ability to protect its intellectual property for GTx-104; and (ix) legislative, regulatory, political and economic developments. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in the “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission (SEC) and other documents that have been and will be filed by Grace Therapeutics from time to time with the SEC and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Grace Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws.

For more information, please contact:

Grace Therapeutics Contact:
Prashant Kohli
Chief Executive Officer
Tel: 609-322-1602
Email: info@gracetx.com
www.gracetx.com
Investor Relations:
LifeSci Advisors
Mike Moyer
Managing Director
Phone: 617-308-4306
Email: mmoyer@lifesciadvisors.com

GRACE THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)

		September 30, 2026		March 31, 2026
(Expressed in thousands except share data)		$			$
Assets
Current assets:
Cash and cash equivalents		21,311			16,977
Receivables		20			20
Prepaid expenses		629			383
Total current assets		21,960			17,380
Equipment, net		5			8
Intangible assets		27,595			41,128
Goodwill		8,138			8,138
Total assets		57,698			66,654
Liabilities and Stockholders’ equity
Current liabilities:
Trade and other payables		1,614			2,146
Total current liabilities		1,614			2,146
Deferred tax liability		604			612
Total liabilities		2,218			2,758
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding as of September 30, 2026 and March 31, 2026		—			—
Common stock, $0.0001 par value per share; 100,000,000 authorized; 21,035,930 and 16,024,026 shares issued and outstanding as of September 30, 2026 and March 31, 2026, respectively		2			1
Additional paid-in capital		307,917			298,413
Accumulated other comprehensive loss		(6,038	)		(6,038	)
Accumulated deficit		(246,401	)		(228,480	)
Total stockholders’ equity		55,480			63,896
Total liabilities and stockholders’ equity		57,698			66,654

GRACE THERAPEUTICS, INC.
Condensed Consolidated Statements of Loss and Comprehensive Loss
(Unaudited)

		Three months ended										Six months ended
		September 30, 2026					September 30, 2025					September 30, 2026					September 30, 2025
(Expressed in thousands, except share and per share data)
			$					$					$					$
Operating expenses
Research and development expenses				(885	)				(568	)				(1,582	)				(1,523	)
General and administrative expenses				(1,407	)				(1,961	)				(3,094	)				(4,096	)
Impairment of intangible assets				—					—					(13,533	)				—
Loss from operating activities				(2,292	)				(2,529	)				(18,209	)				(5,619	)
Foreign exchange (loss) gain				(1	)				(8	)				(15	)				3
Change in fair value of derivative warrant liabilities				—					1,427					—					940
Interest and other income, net				154					172					295					375
Total other income, net				153					1,591					280					1,318
Loss before income tax benefit				(2,139	)				(938	)				(17,929	)				(4,301	)
Income tax benefit				8					—					8					—
Net loss and total comprehensive loss				(2,131	)				(938	)				(17,921	)				(4,301	)
Basic and diluted loss per share			($0.11		)			($0.06		)			($0.96		)			($0.27		)
Weighted-average number of shares outstanding				20,116,776					15,924,522					18,701,159					15,924,522

---

• Sharpens focus on our higher margin product portfolio, accelerating progress towards Astec’s 2030 strategic objectives
• Enterprise value of $75 million, subject to customary closing adjustments
• Expected to be accretive to annualized EPS through the divestiture of a business generating operating losses and to improve the Company’s adjusted EBITDA margin by approximately 200 basis points
• Strengthens financial flexibility to support organic growth and strategic investments

CHATTANOOGA, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) — Astec Industries, Inc. (Nasdaq: ASTE) (“Astec” or the “Company”) today announced that it has entered into a definitive agreement to sell its road construction equipment business, including the Roadtec and Carlson brands (the “Roadtec Business”), to Komatsu America Corp., a subsidiary of Komatsu Ltd. (collectively, “Komatsu”), for an enterprise value of $75 million, subject to customary closing adjustments.

The Roadtec Business, based in Chattanooga, Tennessee, designs, manufactures and supports equipment used in road construction and resurfacing, including highway-class and commercial-class asphalt pavers, paver screeds, Shuttle Buggy® material transfer vehicles and cold planers, as well as related aftermarket parts and rebuild services.

The Roadtec Business, which is reported within Astec’s Infrastructure Solutions segment, generates approximately $145 million in annualized revenue. The divestiture is expected to eliminate associated operating losses and be accretive to Astec’s annualized EPS.

Use of Proceeds

Astec expects to realize approximately $65 million in total expected cash proceeds and tax benefits associated with the sale. The cash proceeds are expected to strengthen Astec’s balance sheet and provide additional financial flexibility to invest in its core businesses and pursue strategic acquisitions, consistent with the Company’s disciplined capital allocation strategy.

The divestiture will also enable Astec to further prioritize investment in its core asphalt, aggregates and concrete platforms, as well as growth opportunities in recycling, digital solutions and mining.

Jaco van der Merwe, Astec President and Chief Executive Officer, said, “The Roadtec Business has been an important part of Astec, and I want to thank our Roadtec employees for their dedication and contributions and our customers for their partnership and loyalty over the years. We are pleased to have entered into this agreement with Komatsu, a strategic buyer who values the Roadtec brand, technology, engineering expertise and team members. This transaction is consistent with our strategy to sharpen our portfolio focus, drive sustainable margin expansion and allocate capital toward our core businesses and long-term growth opportunities.”

The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions.

Evercore is serving as financial advisor to Astec, and Alston & Bird LLP is serving as legal counsel.

About Astec

Astec, (www.astecindustries.com), is a manufacturer of specialized equipment for asphalt road building, aggregate processing and concrete production. Astec’s manufacturing operations are divided into two primary business segments: Infrastructure Solutions that includes road building, asphalt and concrete plants, thermal and storage solutions; and Materials Solutions that include aggregate processing, mining and recycling equipment. Astec also operates a line of controls and automation products designed to deliver enhanced productivity through improved equipment performance.

Forward-Looking Statements

This News Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements relate to, among other things, the anticipated benefits, financial effects and timing of the proposed divestiture of the Roadtec Business. Statements in this News Release that are not historical are hereby identified as “forward-looking statements” and may be indicated by words or phrases such as “anticipates,” “plans,” “projects,” “expects,” “believes,” “should,” “would,” “could,” “forecast,” “management is of the opinion,” use of the future tense and similar words or phrases. These forward-looking statements are based largely on management’s expectations, which are subject to a number of known and unknown risks, uncertainties and other factors. These risks and uncertainties include, but are not limited to: the timing to consummate the divestiture of the Roadtec Business and the risk that the divestiture of the Roadtec Business may not be completed at all or the occurrence of any event, change, or other circumstances that could give rise to the termination of the definitive agreement; the risk that the conditions to the closing of the divestiture of the Roadtec Business may not be satisfied or waived; the diversion of management’s time on transaction-related issues; the ability to successfully divest the Roadtec Business and realize the anticipated benefits of the divestiture of the Roadtec Business, including cost savings and other efficiencies from the divestiture of the Roadtec Business; and other risks discussed and described in Astec’s most recent Annual Report on Form 10-K, including those risks described in Part I, Item 1A, “Risk Factors,” thereof, and in other reports filed subsequently by us with the Securities and Exchange Commission. All forward-looking statements included in this News Release are based on information available to us on the date hereof, and Astec assumes no obligation to update any such forward-looking statements to reflect future events or circumstances, except as required by law.

For Additional Information Contact:

Steve Anderson
Senior Vice President of Administration and Investor Relations
Phone: (423) 899-5898
E-mail: sanderson@astecindustries.com

TR-1: Standard form for notification of major holdings

1. Issuer Details
ISIN
GB00B02J6398
Issuer Name
ADMIRAL GROUP PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Wellington Management Group LLP
City of registered office (if applicable)
Boston
Country of registered office (if applicable)
United States
4. Details of the shareholder

Name	City of registered office	Country of registered office
VIDACOS NOMINEES LIMITED
State Street Nominees Limited
ROY Nominees Limited
Nortrust Nominees Limited
Mellon Nominees (UK) Ltd.
JP Morgan Chase Nominees Limited
HSBC Global Custody Nominee (UK) Limited
GOLDMAN SACHS INTERNATIONAL
BNY (OCS) Nominees Limited
BBH ISL NOMINEES LTD

5. Date on which the threshold was crossed or reached
11-Nov-2026
6. Date on which Issuer notified
12-Nov-2026
7. Total positions of person(s) subject to the notification obligation

.	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	4.880000	0.080000	4.960000	15162163
Position of previous notification (if applicable)	4.920000	0.090000	5.010000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00B02J6398		14894312		4.880000
Sub Total 8.A	14894312		4.880000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Equity swap	05/05/2028	05/05/2028	Cash	1172	0.000000
Equity swap	15/05/2033	15/05/2033	Cash	102864	0.030000
Equity swap	20/05/2033	20/05/2033	Cash	120175	0.040000
Equity swap	30/05/2028	30/05/2028	Cash	7019	0.000000
Equity swap	31/05/2033	31/05/2033	Cash	36621	0.010000
Sub Total 8.B2				267851	0.080000%

9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Wellington Management Group LLP (Chain 1)	Wellington Group Holdings LLP
Wellington Management Group LLP (Chain 1)	Wellington Investment Advisors Holdings LLP
Wellington Management Group LLP (Chain 1)	Wellington Management Global Holdings, Ltd.
Wellington Management Group LLP (Chain 1)	Wellington Management Hong Kong Ltd
Wellington Management Group LLP (Chain 2)	Wellington Group Holdings LLP
Wellington Management Group LLP (Chain 2)	Wellington Investment Advisors Holdings LLP
Wellington Management Group LLP (Chain 2)	Wellington Management Global Holdings, Ltd.
Wellington Management Group LLP (Chain 2)	Wellington Management International Ltd
Wellington Management Group LLP (Chain 3)	Wellington Group Holdings LLP
Wellington Management Group LLP (Chain 3)	Wellington Investment Advisors Holdings LLP
Wellington Management Group LLP (Chain 3)	Wellington Management Company LLP
Wellington Management Group LLP (Chain 4)	Wellington Group Holdings LLP
Wellington Management Group LLP (Chain 4)	Wellington Investment Advisors Holdings LLP
Wellington Management Group LLP (Chain 4)	Wellington Management Global Holdings, Ltd.
Wellington Management Group LLP (Chain 4)	Wellington Management Europe GmbH

10. In case of proxy voting
Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

If date does not apply, explain below

11. Additional Information
Wellington Management Company LLP is an investment management entity that manages the assets of certain funds and/or managed accounts.
Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

Wellington Management International Ltd, Wellington Management Hong Kong Ltd and Wellington Management Europe GmbH are investment management entities that manage the assets of certain funds and/or managed accounts.
Wellington Management International Ltd, Wellington Management Hong Kong Ltd and Wellington Management Europe GmbH are direct controlled undertakings of Wellington Management Global Holdings, Ltd., which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.
12. Date of Completion
12-Nov-2026
13. Place Of Completion
London, UK

Adeia’s new Clickable Video and Digital Wallet frictionless checkout technologies can be implemented by e-commerce retailers to simplify the path to purchase

SAN JOSE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA), the technology company known for developing foundational innovations that enable next-generation solutions, today announced new e-commerce technologies developed by its in-house R&D team, including interactive Clickable Video and a Digital Wallet architecture designed to enable frictionless checkout. These technologies can be integrated into retailers’ e-commerce platforms, products and services to create more engaging shopping experiences, simplify the path to purchase, and help drive higher conversion rates.

The potential of shoppable video is clear; building a seamless path from viewer interest to completed purchase remains the challenge. Current implementations route viewers through QR codes, browser redirects, and multi-step checkout flows that break at the moment of peak purchase intent. Adeia has spent years inventing and developing the technology that closes that gap. Rather than connecting video services to individual merchants, the company’s Digital Wallet architecture links video services directly to digital wallet providers, letting consumers use their existing payment credentials and reducing the buying process to three simple steps: see it, pick up your phone, push a button.

Adeia’s Clickable Video technology extends the shoppable experience beyond featured products. Using proprietary computer vision, it analyzes video streams, identifies objects and matches them to e-commerce inventory in real time, without manual tagging — turning nearly anything a viewer sees on screen into a purchasable item through a pre-packaged digital cart.

The platform works across connected TVs, OTT services, live events and content, creating net-new monetization paths for streaming platforms, TV OEMs, OS providers, platform players, online marketplaces, brands, e-tailers and influencers. With digital wallet adoption projected to exceed 5.2 billion users — more than 60% of the world’s population — in 2026, according to Juniper Research, the infrastructure decisions being made today will determine who owns the e-commerce layer in streaming, and Adeia’s IP portfolio is built to be that foundation.

“AI is fundamentally changing the e-commerce technology stack and the way consumers discover products, make purchasing decisions and complete transactions in an agentic world,” said Serhad Doken, chief technology officer at Adeia. “These new technologies will allow platform providers, brands, e-tailers, and merchants to offer a controlled, distraction-free purchase environment, that doesn’t currently exist in today’s static curated cart model.”

Adeia’s e-commerce technologies are licensed by a growing number of industry-leading retailers and digital commerce companies, as well as major e-commerce platforms, online marketplaces and other significant companies that enable and deliver modern social and online shopping experiences.

About Adeia

Adeia Inc. (Nasdaq: ADEA) develops foundational innovations that shape how the world computes, connects and experiences entertainment. Its inventions span a broad range of semiconductor and media technologies, including 3D interconnect (hybrid bonding) and advanced thermal management for AI datacenters, as well as content discovery, personalization, and streaming. These inventions are licensed to leaders across the chip design and manufacturing, consumer electronics, automotive, digital entertainment, and e-commerce industries. Adeia’s innovations enable more powerful and efficient products, and more immersive, personalized experiences across billions of devices worldwide. Learn more at www.adeia.com.

For Information Contact

Investor Relations
Chris Chaney
IR@adeia.com

Media Relations
‍Anna Enerio
marketing@adeia.com